Oryzon Genomics, S.A.
Oryzon develops experimental medicines that change how cells regulate gene activity, with clinical programmes in blood cancers and psychiatric and neurological conditions. Its treatments are still being tested and have not been approved for sale.
Overview
Latest results
Latest financial publication
9M 2026 financial results
Investment Thesis
Clinical evidence and funding determine the next steps
European Tech Equities analysis ·
The investment case
Oryzon’s value depends on turning experimental biology into medicines that help patients. Clinical data, regulatory decisions and access to capital matter more than current sales, which are zero. A successful licensing agreement could share development costs, but none should be assumed.
Business progress
The November update reports preliminary responses in small iadademstat studies and authorisation of the VIVALDI trial in Spain. These are development steps, not proof of benefit in a large comparative trial. PORTICO-2, the proposed Phase III vafidemstat trial, still requires regulatory preparation.
Customer demand
Unmet medical needs create a reason to study these drugs, not guaranteed demand for an approved product. Doctors, regulators and payers will need convincing evidence on benefit, side effects and comparison with existing therapies.
Financial position
Oryzon held €19.1 million in cash at September 2026 and reported a nine-month net loss of €2.6 million. Capitalised development spending means that the accounting loss understates total cash invested in research. The proposed €125 million capital increase could materially dilute existing holders if approved and completed.
Value and risks
There is no recurring earnings base on which to judge a conventional earnings multiple. Assessment depends on the probability, cost and timing of clinical success, future commercial rights and the number of shares needed to fund development. A promising early result can still fail in a larger trial.
What would weaken the case
- Clinical trials can fail or be delayed.
- New funding can dilute existing shareholders.
- Development assets may need impairment if a programme fails.
Sources
Financials
The business in numbers
Latest
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
No commercial revenue is reported. Capitalised development is investment in intangible assets, not sales; tax credits affect the net result. Nine-month 2026 statements contain income and balance-sheet data but no cash-flow statement. FY2024 figures are restated comparators.
Annual
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
No commercial revenue is reported. Capitalised development is investment in intangible assets, not sales; tax credits affect the net result. Nine-month 2026 statements contain income and balance-sheet data but no cash-flow statement. FY2024 figures are restated comparators.
Half-year
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
No commercial revenue is reported. Capitalised development is investment in intangible assets, not sales; tax credits affect the net result. Nine-month 2026 statements contain income and balance-sheet data but no cash-flow statement. FY2024 figures are restated comparators.
Year to date
Income statement
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
No commercial revenue is reported. Capitalised development is investment in intangible assets, not sales; tax credits affect the net result. Nine-month 2026 statements contain income and balance-sheet data but no cash-flow statement. FY2024 figures are restated comparators.
Performance
About these figures
Dates link to the original reports. Bars compare the same period a year earlier, on a consistent accounting basis. Arrows show whether the number rose or fell, not whether it is good or bad for the business.
Research & updates
Oryzon calls shareholder meeting on proposed capital increase
ORYZON reports third quarter 2026 financial results and provides corporate update
9M 2026 financial results
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Interviews
Interviews are coming soon
No interviews with Oryzon Genomics, S.A. have been published yet.
Sources
Sources & data dates
Financial figures link to the company’s publications and retain their reporting period. Share prices have their own closing dates.
9M 2025 · Published Nov 10, 2026 · Checked Nov 15, 2026
9M 2026 · Published Nov 10, 2026 · Checked Nov 15, 2026
H1 2025 · Published Jul 27, 2026 · Checked Nov 15, 2026
H1 2026 · Published Jul 27, 2026 · Checked Nov 15, 2026
FY 2024 · Published Feb 27, 2026 · Checked Nov 15, 2026
FY 2025 · Published Feb 27, 2026 · Checked Nov 15, 2026
Checked 2026-11-15
Checked 2026-11-15
Checked 2026-11-15
Checked 2026-11-15
